Market Eyes LiveAlnylam Pharmaceuticals, Inc. (ALNY) Stock Rating & Analysis
MELANY's data-driven read on Alnylam Pharmaceuticals, Inc. · Pharmaceutical Preparations.
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics. RNAi is a naturally occurring cellular pathway for sequence-specific silencing and regulation of gene expression. Its commercial RNAi products, all developed and commercialized by Alnylam, include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1).
Why ALNY scores 55/100
MELANY scores Alnylam Pharmaceuticals, Inc. 55/100 by weighing eight factors. Here is how ALNY breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 16.5x, earnings growth accelerating
- PEG ratio 0.42 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 81%
- ROE 99%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Avg EPS beat +45%
What Wall Street price targets and revisions are signalling.
- Analyst targets 73% upside
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for ALNY
- High debt-to-equity ratio 2.2x, rate-sensitive balance sheet
- Weak price momentum, trend not yet confirmed, may need more time to set up
Sector and theme context
Alnylam Pharmaceuticals, Inc. sits in the Healthcare sector theme, which MELANY currently rates 38/100 for strength. Theme strength feeds ALNY's momentum and catalyst factors above.
Tracking ALNY
Alnylam Pharmaceuticals, Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add ALNY to your watchlist and get alerted the moment the rating changes.
How MELANY rates ALNY
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Alnylam Pharmaceuticals, Inc.'s 55/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ALNY
Is Alnylam Pharmaceuticals, Inc. (ALNY) a buy?
As of 2026-08-10, MELANY rated Alnylam Pharmaceuticals, Inc. Hold with a composite score of 55/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Alnylam Pharmaceuticals, Inc.'s MELANY score?
Alnylam Pharmaceuticals, Inc. (ALNY) has a MELANY composite score of 55/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the ALNY stock rating calculated?
MELANY scores ALNY from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Alnylam Pharmaceuticals, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Alnylam Pharmaceuticals, Inc. (ALNY) Hold with a composite of 55/100 as of 2026-08-10. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ALNY stock price forecast?
MELANY does not publish price targets or forecasts for ALNY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 55/100 across eight factors for Alnylam Pharmaceuticals, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ALNY stock overvalued or undervalued?
MELANY's valuation factor currently reads 42/100 for Alnylam Pharmaceuticals, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ALNY's read.
What price should I buy ALNY at?
MELANY is not flagging a fresh entry for ALNY at its current Hold rating, so there is no entry zone to publish right now. Watchlisting ALNY in the free app gets you alerted the moment that changes.
What are the risks of buying ALNY stock?
The top risks MELANY currently flags for Alnylam Pharmaceuticals, Inc.: High debt-to-equity ratio 2.2x, rate-sensitive balance sheet; Weak price momentum, trend not yet confirmed, may need more time to set up. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Alnylam Pharmaceuticals, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 71/100 for Alnylam Pharmaceuticals, Inc., and earnings track record, at 88/100. The 55/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ALNY stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 15/100 for ALNY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ALNY rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-10. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ALNY continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
ALNY's live rating and alerts are free either way. The app is our flagship.